Clinical trial
TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With…
NCT00023413 · Centers for Disease Control and Prevention, U.S. Fed · Completed
Key facts
| NCT number | NCT00023413 |
|---|---|
| Title | TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz |
| Official title | TBTC Study 23C: Intensive Pharmacokinetic Study of Intermittent Rifabutin and Isoniazid With Daily Efavirenz in Combination With Two Nucleoside Analogs for Treatment of HIV and Tuberculosis Co-infections |
| Lead sponsor | Centers for Disease Control and Prevention, U.S. Fed |
| Collaborators | US Department of Veterans Affairs U.S. Fed |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections, Tuberculosis |
| Intervention type | Drug |
| Interventions | Rifabutin, Efavirenz |
| Enrollment | 20 |
| Start date | Nov 1, 1999 |
| Primary completion | Feb 1, 2004 |
| Completion | Feb 1, 2004 |
| First posted | Sep 10, 2001 |
| Last update posted | Jun 5, 2012 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: